

EMA/429589/2023

European Medicines Agency decision P/0424/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a waiver for vibostolimab / pembrolizumab (EMA-003063-PIP03-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0424/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a waiver for vibostolimab / pembrolizumab (EMA-003063-PIP03-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Merck Sharp & Dohme (Europe) Inc. on 19 December 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 September 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for vibostolimab / pembrolizumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for vibostolimab / pembrolizumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Merck Sharp & Dohme (Europe) Inc., 5 Lynxbinnenhof, 1200 – Brussels, Belgium.

EMA/PDCO/259140/2023
Amsterdam, 8 September 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA-003063-PIP03-22

Scope of the application

Active substance(s):

Vibostolimab / pembrolizumab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of melanoma

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe) Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe) Inc. submitted for agreement to the European Medicines Agency on 19 December 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 30 January 2023.

Supplementary information was provided by the applicant on 30 May 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of melanoma

The waiver applies to:

- the paediatric population from birth to less than 12 years of age;
- concentrate for solution for infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of melanoma

2.1.1. Indication(s) targeted by the PIP

Adjuvant treatment of resected high-risk melanoma in adolescent patients aged 12 years and older

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

| Area | Description |
|----------------------------------|---|
| Quality-related studies | Not applicable |
| Non-clinical studies | Not applicable |
| Clinical studies | Not applicable |
| Modelling and simulation studies | Study 1 Pharmacokinetic modeling and simulation study to select the vibostolimab/pembrolizumab (MK-7684) dose in adolescents from 12 years to less than 18 years of age for treatment of melanoma. |
| Other studies | Not applicable |
| Extrapolation plan | Studies KV-010 [study of adjuvant pembrolizumab/vibostolimab (MK-7684A) versus pembrolizumab for resected high-risk melanoma in participants with high-risk stage II-IV melanoma; adolescent and adult data] and MK-9999-01B (paediatric platform substudy in the |

| | |
|--|--|
| | adolescent melanoma population; paediatric data) along with modelling and simulation Study 1 are part of an extrapolation plan covering the paediatric population from 12 years to less than 18 years of age for the treatment of melanoma, as agreed by the PDCO. |
|--|--|

3. Follow-up, completion and deferral of PIP

| | |
|---|-------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By May 2026 |
| Deferral for one or more measures contained in the paediatric investigation plan: | No |

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.